Skip to main content

Advertisement

SpringerLink
Log in

Genetic factors in the predisposition to drug-induced hypersensitivity reactions

  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Drug hypersensitivity reactions can occur with most drugs, although the frequency, severity, and clinical manifestations vary. Case reports have suggested that there may be familial clustering of drug hypersensitivity suggesting a genetiv predisposition. As with most other forms of drug response, predisposition to drug hypersensitivity reactions is likely to be multifactorial and multigenic. Given the immune pathogenesis of these reactions, it is perhaps not surprising that the most significant genetic associations have been identified in the major histocompatibility complex for drugs such as abacavir, carbamazepine, and allopurinol. For abacavir, it has been suggested that preprescription genotyping for HLA-B*5701 in whites may reduce the incidence of hypersensitivity. It is likely that as our knowledge of variation in the human genome improves, coupled with improvements in technology, many more significant genetic predisposing factors for drug hypersensitivity are likely to be identified in the next decade. However, as we search for these genetic factors, it is important that we do not forget environmental predisposition, and to bear in mind that a genetic marker for drug hypersensitivity in one population may not necessarily be relevant for another population. Notwithstanding the advances in genetic technologies, the ultimate determinant of success in this area of research will be the identification and careful phenotyping of patients with drug hypersensitivity reactions. As we progress to whole genome scanning, in order to satisfy the requirements for adequate statistical power, the identification of large numbers of carefully phenotyped patients will be feasible only through international collaborations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, ed.Textbook of Adverse Drug Reactions. Oxford, UK: Oxford University Press, 1991:18–45.

    Google Scholar 

  2. Demoly P, Gomes ER. Drug hypersensitivities: definition, epidemiology and risk factors.Allerg Immunol (Paris). 2005;37:202–206.

    CAS  Google Scholar 

  3. Chadwick D, Shaw MDM, Foy P, Rawlins MD, Turnbull DM. Serum anticonvulsant concentration and the drug-induced skin eruptions.J Neurol Neurosurg Psychiatry. 1984;47:642–644.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Shear NH, Spielberg SP, Cannon M, Miller M. Anticonvulsant hypersensitivity syndrome: in vitro risk assessment.J Clin Invest. 1988;82:1826–1832.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis: potential role in idiosyncratic drug reactions.Toxicology. 2002;181–182:55–63.

    Article  PubMed  Google Scholar 

  6. Strachan DP, Wong HJ, Spector TD. Concordance and interrelationship of atopic diseases and markers of allergic sensitization among adult female twins.J Allergy Clin Immunol. 2001;108:901–907.

    Article  CAS  PubMed  Google Scholar 

  7. Edwards SG, Hubbard V, Aylett S, Wren D. Concordance of primary generalized epilepsy and CBZ hypersensitivity in monozygotic twins.Postgrad Med J. 1999;75:680–681.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Johnson-Reagan L, Bahna SL. Severe drug rashes in 3 siblings simultaneously.Allergy. 2003;58:445–447.

    Article  CAS  PubMed  Google Scholar 

  9. Peyrieere H, Nicolas J, Siffert M, Demoly P, Hallaire-Buys D, Reynes J. Hypersensitivity related to abacavir in 2 members of a family.Ann Pharmacother. 2001;35:1291–1292.

    Article  CAS  PubMed  Google Scholar 

  10. Pellicano R, Silvestris A, Iannantuono M, Ciavarella G, Lomuto M. Familial occurrence of fixed drug eruptions.Acta Derm Venereol. 1992;72:292–293.

    CAS  PubMed  Google Scholar 

  11. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin.Am J Med. 1991;91:631–634.

    Article  CAS  PubMed  Google Scholar 

  12. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro.N Engl J Med. 1981;305:722–727.

    Article  CAS  PubMed  Google Scholar 

  13. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug-reactions: a mechanistic evaluation of risk-factors.Br J Clin Pharmacol. 1992;34:377–395.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions.Trends Pharmacol Sci. 2001;22:298–305.

    Article  CAS  PubMed  Google Scholar 

  15. Perry HM, Tan EM, Carmody S, Sakamota A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine.J Lab Clin Med. 1970;76:114–125.

    PubMed  Google Scholar 

  16. Batchelor JR, Welsh KI, Tinoco RM, et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility.Lancet. 1980;1:1107–1109.

    Article  CAS  PubMed  Google Scholar 

  17. Naisbitt DJ, Pirmohamed M, Park BK. Immunopharmacology of hypersensitivity reactions to drugs.Curr Allergy Asthma Rep. 2003;3:22–29.

    Article  PubMed  Google Scholar 

  18. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome.Nature. 2001;409:860–921.

    Article  CAS  PubMed  Google Scholar 

  19. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome.Science. 2001;291:1304–1351.

    Article  CAS  PubMed  Google Scholar 

  20. Tsunoda T, Lathrop GM, Sekine A, et al. Variation of gene-based SNPs and linkage disequilibrium patterns in the human genome.Hum Mol Genet. 2004;13:1623–1632.

    Article  CAS  PubMed  Google Scholar 

  21. Walsh EC, Mather KA, Schaffner SF, et al. An integrated haplotype map of the human major histocompatibility complex.Am J Hum Genet. 2003;73:580–590.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir.Clin Ther. 2002;24:565–573.

    Article  CAS  PubMed  Google Scholar 

  23. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome.Arch Intern Med. 1995;155:2285–2290.

    Article  CAS  PubMed  Google Scholar 

  24. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.Clin Ther. 2001;23:1603–1614.

    Article  CAS  PubMed  Google Scholar 

  25. Mallal S, Nolan D, Witt C, et al. Association between presence ofHLA-B * 5701, HLA-DR7, andHLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir.Lancet. 2002;359:727–732.

    Article  CAS  PubMed  Google Scholar 

  26. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.Proc Natl Acad Sci USA. 2004;101:4180–4185.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.Lancet. 2002;359:1121–1122.

    Article  CAS  PubMed  Google Scholar 

  28. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hyperensitivity to abacavir in some, but not all, populations.Pharmacogenomics. 2004;5:203–211.

    Article  CAS  PubMed  Google Scholar 

  29. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.Pharmacogenetics. 2004;14:335–342.

    Article  PubMed  Google Scholar 

  30. Dodd CC, Naisbitt DJ, Vilar FJ, et al. Abacavir hypersensitivity in human immunodeficiency virus-positive patients: demonstration of the presence of drug-specific lymphocyte proliferation in vitro.Br J Clin Pharmacol. 2003;55:421.

    Google Scholar 

  31. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity.AIDS. 2005;19:979–981.

    Article  CAS  PubMed  Google Scholar 

  32. Walsh JS, Reese MJ, Thurmond LM. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes.Chem Biol Interact. 2002;142:135–154.

    Article  CAS  PubMed  Google Scholar 

  33. Lindpaintner K. The importance of being modest: reflections on the pharmacogenetics of abacavir.Pharmacogenomics. 2002;3:835–838.

    Article  PubMed  Google Scholar 

  34. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs.Epilepsia. 1998;39:S8-S16.

    Article  CAS  PubMed  Google Scholar 

  35. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.Lancet. 1999;353:2190–2194.

    Article  CAS  PubMed  Google Scholar 

  36. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4(+) and CD8(+) T cells in individuals allergic to sulfonamides, phenytoin, and CBZ.J Immunol. 1995;155:462–472.

    CAS  PubMed  Google Scholar 

  37. Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity reactions to CBZ: characterization of the specificity, phenotype, and cytokine profile of drug-specific T-cell clones.Mol Pharmacol. 2003;63:732–741.

    Article  CAS  PubMed  Google Scholar 

  38. Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK. An investigation of the formation of cytotoxic, protein-reactive, and stable metabolites from CBZ in vitro.Biochem Pharmacol. 1992;43:1675–1682.

    Article  CAS  PubMed  Google Scholar 

  39. Tybring G, von Bahr C, Bertilsson L, Collste H, Glaumann H, Solbrand M. Metabolism of CBZ and its epoxide metabolite in human and rat liver in vitro.Drug Metab Dispos. 1981;9:561–564.

    CAS  PubMed  Google Scholar 

  40. Kroetz DL, Kerr BM, McFarland LV, Loiseau P, Wilensky AJ, Levy RH. Measurement of in vivo microsomal epoxide hydrolase activity in white subjects.Clin Pharmacol Ther. 1993;53:306–315.

    Article  CAS  PubMed  Google Scholar 

  41. Madden S, Maggs JL, Park BK. Bioactivation of CBZ in the rat in vivo: evidence for the formation of reactive arene oxide(s).Drug Metab Dispos. 1996;24:469–479.

    CAS  PubMed  Google Scholar 

  42. Lertratanangkoon K, Horning MG. Metabolism of CBZ.Drug Metab Dispos. 1982;10:1–10.

    CAS  PubMed  Google Scholar 

  43. Lillibridge JH, Amore BM, Slattery JT, et al. Protein-reactive metabolites of CBZ in mouse liver microsomes.Drug Metab Dispos. 1996;24:509–514.

    CAS  PubMed  Google Scholar 

  44. Pirmohamed M, Graham A, Roberts P, et al. CBZ hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine.Br J Clin Pharmacol. 1991;32:741–749.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Gaedigk A, Spielberg SP, Grant DM. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions.Pharmacogenetics. 1994;4:142–153.

    Article  CAS  PubMed  Google Scholar 

  46. Green VJ, Pirmohamed M, Kitteringham NR, et al. Genetic-analysis of microsomal epoxide hydrolase in patients with CBZ hypersensitivity.Biochem Pharmacol. 1995;50:1353–1359.

    Article  CAS  PubMed  Google Scholar 

  47. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in CBZ-hypersensitive patients.Neurology. 2001;56:890–896.

    Article  CAS  PubMed  Google Scholar 

  48. Alfirevic A, Mills T, Harrington P, et al. Serious CBZ-induced hypersensitivity reactions associated with the HSP70 gene cluster.Pharmacogenetics and Genomics. In press.

  49. Chung W-H, Hung S-I, Hong H-S, et al. Medical genetics: a marker for Stevens-Johnson syndrome.Nature. 2004;428:486.

    Article  CAS  PubMed  Google Scholar 

  50. van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice.J Clin Epidemiol. 1998;51:703–708.

    Article  PubMed  Google Scholar 

  51. Koopmans PP, van der Ven AJAM, Vree TB, van der Meer JWM. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV-infection: allergic or toxic.AIDS. 1995;9:217–222.

    Article  CAS  PubMed  Google Scholar 

  52. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions.Clin Pharmacol Ther. 1991;49:13–17.

    Article  CAS  PubMed  Google Scholar 

  53. Wolkenstein P, Loriot MA, Aractingi S, Cabelguenne A, Beaune P, Chosidow O. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS.Pharmacogenetics. 2000;10:821–828.

    Article  CAS  PubMed  Google Scholar 

  54. Pirmohamed M, Alfirevic A, Vilar J, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity.Pharmacogenetics. 2000;10:705–713.

    Article  CAS  PubMed  Google Scholar 

  55. Alfirevic A, Stalford AC, Vilar FJ, Wilkins EGL, Park BK, Pirmohamed M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity.Br J Clin Pharmacol. 2003;55:158–165.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Pirmohamed M, Naisbitt DJ, Park BK. The danger hypothesis: inflammation and idiosyncratic toxicity.Toxicology. 2001;164:5.

    Google Scholar 

  57. Palmer LJ, Cardon LR. Shaking the tree: mapping complex disease genes with linkage disequilibrium.Lancet. 2005;366:1223–1234.

    Article  CAS  PubMed  Google Scholar 

  58. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Proc Natl Acad Sci USA. 2005;102:4134–4139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis.Lancet. 1991;337:628–630.

    Article  Google Scholar 

  60. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.Lancet. 2004;364:1865–1871.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Therapeutics, The University of Liverpool, Ashton Street, 69 3GE, Liverpool, UK

    Munir Pirmohamed

Authors
  1. Munir Pirmohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Munir Pirmohamed.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pirmohamed, M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J 8, 3 (2006). https://doi.org/10.1208/aapsj080103

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/aapsj080103

Keywords

Search

Navigation